Management Team
Thurein Htoo, MS, MBA
Chief Executive Officer & Co-Founder
Mr. Htoo is the Chief Executive Officer and Co-Founder of Qlaris Bio. Mr. Htoo is a biopharmaceutical strategist primarily focused in ophthalmology and rare disease. He was previously the Chief Business Officer of Qrativ. Before Qrativ, he was VP, Head of Business Development and Corporate Strategy at Novelion Therapeutics where he had helped orchestrate the merger of QLT Inc. and Aegerion Pharmaceuticals to form Novelion. Mr. Htoo has also held leadership roles encompassing business development and disease area strategy in Ophthalmology and Rare Diseases at Pfizer and at NPS Pharmaceuticals.
Mr. Htoo holds an MBA from the University of Rochester, and both an MS in Physiology and a BAS in Neurobiology and in Psychology from UC Davis.
Barbara Wirostko, MD
Chief Medical Officer & Co-Founder
Dr. Wirostko is the Chief Medical Officer and Co-Founder of Qlaris Bio. Dr. Wirostko is a practicing glaucoma specialist and is also a Clinical Adjunct Professor at the University of Utah, Moran Eye Center. She was previously the Chief Medical Officer of EyeGate Pharmaceuticals following its acquisition of Jade Therapeutics where Dr. Wirostko was Co-Founder and Chief Scientific Officer spearheading the development of the Ocular Bandage Gel for human use. Prior to Jade, she served as the Chief Medical Officer of Altheos, a glaucoma company, and held leadership positions in medical and clinical development at Pfizer in Ophthalmology.
Dr. Wirostko received her MD from and completed her residency at Columbia University and holds a BA in Microbiology from Cornell University.
BOARD OF DIRECTORS
Wende Hutton
Andrew Danielsen
Wende Hutton
Ms. Hutton is a General Partner with Canaan Partners. She identifies, builds and invests in companies that change medicine by bringing novel drugs, technologies and devices to market. By partnering with Founders, she has provided guidance and oversight to management teams helping them to deliver over a dozen innovative products to patients.
Ron Hunt
Andrew Danielsen
Wende Hutton
Mr. Hunt is a Managing Director at New Leaf Venture Partners and focuses on early-to-late stage investments in biopharmaceuticals. Since being a Founder of New Leaf Ventures in 2005, he has over two decades of experience investing in and building companies focused on the development of novel medicines that address important unmet medical needs.
.jpg/:/cr=t:0%25,l:8.27%25,w:80.65%25,h:60.86%25/rs=w:365,h:365,cg:true,m)
Andrew Danielsen
Andrew Danielsen
Andrew Danielsen
Mr. Danielsen is the Chair, Licensing at Mayo Clinic Ventures. He oversees the licensing, technology development, and business development functions of the Mayo Clinic Ventures office who are charged with identifying, developing, and commercializing Mayo Clinic intellectual property through collaborations and industry partnerships.
Adrienne Graves
Adrienne Graves
Adrienne Graves
Dr. Graves is a noted global industry leader in ophthalmology. As the former CEO of Santen, Inc. (US), she oversaw multiple product approvals, acquisitions, and partnerships. She currently serves on multiple company boards, including Iveric Bio, Akorn, Nicox S.A., Surface Pharmaceuticals, Oxurion, and TherOptix.
Thurein Htoo
Adrienne Graves
Adrienne Graves
Mr. Htoo is the CEO of Qlaris Bio. In his career, he has continued to drive the identification and development of novel, targeted therapies, particularly in ophthalmology and in rare diseases, that aim to deliver unique and meaningful value to patients, their caregivers, and to all other stakeholders.
Scientific Advisory Board
Michael Fautsch, PhD (Chair)
Michael Fautsch, PhD (Chair)
Michael Fautsch, PhD (Chair)
Dr. Fautsch is Professor of Ophthalmology and Professor of Biochemistry & Molecular Biology at Mayo Clinic. He serves as Research Chair for Ophthalmology at Mayo, focused on the identification of novel glaucoma therapies. He is also the inventor of QLS-101.
Peter Farina, PhD
Michael Fautsch, PhD (Chair)
Michael Fautsch, PhD (Chair)
Dr. Farina is an Executive-in-Residence at Canaan Partners. Dr. Farina was previously the Senior Vice President of Development for Boehringer Ingelheim Pharmaceuticals Inc. and now works with entrepreneurs and to bring innovative medicines to patients.
Alon Harris, MS, PhD, FARVO
Michael Fautsch, PhD (Chair)
Alon Harris, MS, PhD, FARVO
Dr. Harris is Professor of Ophthalmology, Vice Chair of International Research and Academic Affairs, and Director of Ophthalmic Vascular Diagnostic & Research Program at Mount Sinai Hospital. His research focuses on ocular vascular physiology.
Shan Lin, MD
Dan Stamer, PhD, FARVO
Alon Harris, MS, PhD, FARVO
Dr. Lin is a glaucoma specialist at the Glaucoma Center of San Francisco. He was previously Director of Glaucoma Service at UCSF and is Exec. VP of the World Glaucoma Association and Chair of the Ambassador Committee for the American Glaucoma Society.
Janet Serle, MD
Dan Stamer, PhD, FARVO
Dan Stamer, PhD, FARVO
Dr. Serle is Professor of Ophthalmology and the Director of both the Glaucoma Clinical and Research Fellowships at the Mount Sinai School of Medicine. She is the Program Chair of the NY Glaucoma Society and is on the Editorial Board of the Journal of Glaucoma.
Dan Stamer, PhD, FARVO
Dan Stamer, PhD, FARVO
Dan Stamer, PhD, FARVO
Dr. Stamer is Professor of Ophthalmology and Professor of Biomedical Engineering at Duke Eye Center. He is the current ARVO President and is a leading expert conventional outflow facility and is focused on new drug identification.
Carol Toris, PhD
Dr. Toris is Professor of Ophthalmology and the Director of Glaucoma Research at the University of Nebraska Medical Center. Dr. Toris is focused on preclinical research in aqueous humor dynamics and in the clinical study of drugs lowering intraocular pressure.
Our Investors
